Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Noscapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.98 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.98 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.98 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.98 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.98 |
| ▸ | TUBB | P07437 | 5/20 | 0.98 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.98 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Noscapine SCHEMBL29387578 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAKDM4E | |
| Noscapine SCHEMBL1405962 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAKDM4E | |
| Noscapine SCHEMBL31229945 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2C9CYP2C19LMNAKDM4E | |
| Noscapine SCHEMBL21963688 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2C9CYP2C19LMNAKDM4E | |
| Noscapine SCHEMBL12481369 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAKDM4E | |
| Noscapine SCHEMBL7862895 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAKDM4E | |
| Noscapine SCHEMBL4559 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAKDM4E | |
| Noscapine SCHEMBL14400084 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAKDM4E | |
| Noscapine SCHEMBL2494164 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAKDM4E | |
| Noscapine SCHEMBL10307295 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1055 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025009819-A1 | CUTTABLE AND CONSUMABLE TAPE-TYPE OR BAR-TYPE PREPARATION ENABLING DRUG DOSE CONTROL THROUGH LENGTH | 충북대학교 산학협력단 | 2025-01-09 | — | — | WO | claimed |
| CN-115252814-A | Cyclodextrin-metal organic framework composition and preparation method thereof | 中国科学院上海药物研究所 | 2022-11-01 | — | — | CN | claimed |
| CN-113425847-A | Tablet coating film, raw material composition and preparation thereof, controlled-release tablet and preparation thereof | 上海汉都医药科技有限公司 | 2021-09-24 | — | — | CN | claimed |
| US-20200339649-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2020-10-29 | — | — | US | claimed |
| EP-3645031-A1 | PEPTIDE ANALOGS | Adepthera LLC (US) | 2020-05-06 | — | — | EP | claimed |
| WO-2019005623-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC (US) | 2019-01-03 | — | — | WO | claimed |
| CN-105801588-B | A kind of narcotine derivative and its preparation method and application | 长沙凯得尔森生物技术有限公司 | 2018-09-18 | — | — | CN | claimed |
| WO-2018152554-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | ATTENUA, INC. (US) | 2018-08-23 | — | — | WO | claimed |
| EP-3328383-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | Attenua, Inc. (US) | 2018-06-06 | — | — | EP | claimed |
| CN-107847493-A | ANTITUSSIVE COMPOSITIONS AND METHODS | 阿提努公司 | 2018-03-27 | — | — | CN | claimed |
| US-20060148837-A1 | Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction | EVERETT LABORATORIES, INC. | 2006-07-06 | — | — | US | claimed |
| US-20060062810-A1 | Microemulsion concentrate for oral administration of water-insoluble anti-cold drug and method for preparing same | HANMI PHARM CO., LTD. (KR) | 2006-03-23 | — | — | US | claimed |
| WO-2005094832-A1 | COMPOSITIONS COMPRISING MELOXICAM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | WO | claimed |
| EP-1558214-A1 | MICROEMULSION CONCENTRATE FOR ORAL ADMINISTRATION OF WATER-INSOLUBLE ANTI-COLD DRUG AND METHOD FOR PREPARING SAME | Hanmi Pharm. Co., Ltd. (KR) | 2005-08-03 | — | — | EP | claimed |
| US-20050152975-A1 | Pharmaceutical composition | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-07-14 | — | — | US | claimed |
| WO-2004041249-A1 | MICROEMULSION CONCENTRATE FOR ORAL ADMINISTRATION OF WATER-INSOLUBLE ANTI-COLD DRUG AND METHOD FOR PREPARING SAME | HANMI PHARM. CO., LTD. (KR) | 2004-05-21 | — | — | WO | claimed |
| US-20040022848-A1 | Medicinal composition | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-05 | — | — | US | claimed |
| EP-1319399-A1 | MEDICINAL COMPOSITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-18 | — | — | EP | claimed |
| EP-1161956-A1 | MEDICINAL COMPOSITIONS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-12-12 | — | — | EP | claimed |
| US-5100898-A | Antitussive liquid compositions containing dyclonine | RICHARDSON-VICKS INC. (US) | 1992-03-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050152975-A1 | Pharmaceutical composition | TAS2R5, TAS2R60, TAS2R16 | ADRB1 3500/4885HTR2A 1644/4885AGTR1 1988/4885 |
| US-20200339649-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | ADRB1 138/4885HTR2A 351/4885AGTR1 187/4885 |
| US-20040022848-A1 | Medicinal composition | CD44, CMA1, ACLY | ADRB1 2249/4885HTR2A 943/4885AGTR1 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.